SwanBio Therapeutics

Tom Anderson
Florian Eichler
Rachel Salzman
Karen Kozarsky
% Shareholding
Number of employees
Raised in a Series B in May 2022

Unless stated all financials at 31 December 2023.

Swanbio website

SwanBio Therapeutics is a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of genetically defined neurological conditions.

SwanBio Therapeutics is dedicated to developing genetic medicines for the treatment of serious neurological diseases with significant unmet need.

Founded in partnership with industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialisation expertise.

SwanBio is using adeno-associated viruses (AAVs) to deliver therapeutic genes directly to the central nervous system to achieve profound therapeutic effects. Clinical studies have shown AAVs can be promising vectors for delivering therapeutic DNA and have been shown to be safe and effective in multiple clinical trials, including in other neurological disorders.

SwanBio is developing an AAV-based gene therapy for a rare inherited neurodegenerative disease in which the causative gene is definitively known and well characterised. While their initial focus is on diseases that are both rare and serious, the broader vision is understanding the origin and treatment of disorders where therapeutic DNA has the potential to treat a range of neurological illnesses.

Investment thesis

  • Gene therapy has the potential be transformational in neurology
  • Lead programme targeting Adrenomyeloneuropathy (AMN), an inherited neurodegenerative disease in which the causative gene is definitively known and well characterised
  • One-off delivery mechanism and multiple tractable pipeline programmes

Unmet medical need

  • Hundreds of single gene neurological disorders with poor or no treatment options
  • Lead programme targeting one of the most common monogenic neurological disorders, a severely debilitating progressive movement disorder with no available therapies

Market opportunity*

  • AMN impacts 8,000-10,000 male patients in the US and EU5

* SwanBio analysis

The SwanBio Therapeutics pipeline

Best ideas Pre-clinical Clinical Late Clinical BLA
  • SBT101 - AMN

Syncona team

John Tsai

John Tsai

John Tsai is an Executive Partner of Syncona Investment Management Limited He is currently the CEO of Forcefield Therapeutics, Chair of SwanBio Therapeutics and a Board member of Mosaic Therapeutics. As an Executive Partner at Syncona, John works closely with Lead Partners and the wider investment team to support evaluation and execution of new and existing opportunities at Syncona, utilising his…
View John's biography
Executive Chair
Alex Hamilton

Alex Hamilton

Alex is an Investment Partner of Syncona Investment Management Ltd. He is a Director on the Boards of SwanBio Therapeutics and Anaveon. Previously, he was a member of the Healthcare Investment Banking team at Jefferies, where he worked on a range of financings and mergers and acquisitions across the biotechnology, pharmaceutical and healthcare sectors. Alex has a PhD in Immunology from the Univers…
View Alex's biography
Board member

SwanBio Therapeutics leaders and founders

Other clinical portfolio companies